Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 08/21/2026 | CALL | $60.00 | 4,355 | +3,734 | +601.29% |
| 01/15/2027 | CALL | $65.00 | 9,915 | +2,818 | +39.71% |
| 06/12/2026 | PUT | $53.00 | 2,185 | +2,075 | +1,886.36% |
| 07/17/2026 | CALL | $55.00 | 1,632 | +1,181 | +261.86% |
| 06/18/2026 | PUT | $54.00 | 1,069 | +946 | +769.11% |
| 06/05/2026 | PUT | $55.00 | 3,387 | +943 | +38.58% |
| 09/18/2026 | CALL | $62.50 | 3,449 | -105 | -2.95% |
| 06/18/2026 | CALL | $57.50 | 16,931 | -252 | -1.47% |
| 06/18/2026 | PUT | $56.00 | 993 | -407 | -29.07% |
| 06/18/2026 | CALL | $60.00 | 13,101 | -432 | -3.19% |
| 06/05/2026 | PUT | $54.00 | 2,337 | -459 | -16.42% |
| 07/17/2026 | CALL | $65.00 | 3,156 | -580 | -15.52% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.07% | 64.63M | 4.03B |
| Vanguard 500 Index Fund | 2.34% | 49.15M | 3.06B |
| Fidelity 500 Index Fund | 1.11% | 23.31M | 1.45B |
| SPDR S&P 500 ETF Trust | 1.09% | 23.02M | 1.43B |
| iShares Core S&P 500 ETF | 0.90% | 18.98M | 1.18B |
| Vanguard Index-Value Index Fund | 0.87% | 18.37M | 1.14B |
| JP Morgan Equity Income Fund | 0.82% | 17.35M | 1.08B |
| Select Sector SPDR Fund-Health Care | 0.82% | 17.27M | 1.08B |
| American Mutual Fund Inc | 0.78% | 16.49M | 1.03B |
| Vanguard Institutional Index Fund-Institutional Index Fund | 0.71% | 14.9M | 927.91M |
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
06/02 05:12 pm
The Motley Fool
Read moreWhy Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
06/01 11:15 pm
The Motley Fool
Read moreCRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
06/01 12:30 pm
The Motley Fool
Read moreCRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
05/31 12:11 pm
The Motley Fool
Read moreGlobale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
05/30 02:15 pm
GlobeNewswire Inc.
Read moreGlobal Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
05/30 02:15 pm
GlobeNewswire Inc.
Read moreBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
05/22 05:00 am
GlobeNewswire Inc.
Read moreBioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung
05/22 05:00 am
GlobeNewswire Inc.
Read moreThe Most Undervalued Healthcare Stock in the S&P 500 Right Now
05/21 07:05 am
The Motley Fool
Read moreAnthropic And OpenAI--Building Different Competitive Advantages
05/20 02:18 pm
Benzinga
Read moreBristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
05/20 01:09 pm
Benzinga
Read moreTempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts
05/14 02:23 pm
Benzinga
Read moreGlobal Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
05/13 01:00 pm
GlobeNewswire Inc.
Read moreAstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements
05/12 10:03 am
Benzinga
Read moreWall Street's Cardiac Bet: Where Diagnostics Meet the Money
05/12 08:30 am
Benzinga
Read moreIs Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors.
05/11 09:15 pm
The Motley Fool
Read moreGlobal Personalized Medicine to Transform Modern Healthcare and Cross USD 1 Trillion by 2034 | DelveInsight
05/11 01:00 pm
GlobeNewswire Inc.
Read moreWhy Bristol Myers Squibb Stock Rocked the Market Today
04/30 04:17 pm
The Motley Fool
Read moreWhy Is Bristol-Myers Squibb Stock Trading Higher On Thursday?
04/30 02:12 pm
Benzinga
Read moreRheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape
04/28 01:00 pm
GlobeNewswire Inc.
Read moreAI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive Innovation
04/27 01:36 pm
GlobeNewswire Inc.
Read morePeripheral T-Cell Lymphoma Market to Witness Significant Expansion at a CAGR of 7% During the Forecast Period (2026–2036) Amid Advancing Treatment Landscape | DelveInsight
04/27 01:00 pm
GlobeNewswire Inc.
Read more3 Biotech Stocks That Could Benefit from the Patent Cliff
04/27 11:29 am
Investing.com
Read moreVulvar Cancer Market Global and Regional Analysis Report 2025-2035, Profiles of Merck & Co., Bristol Myers Squibb, and AstraZeneca
04/22 05:59 am
GlobeNewswire Inc.
Read moreFollicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsight
04/21 01:00 pm
GlobeNewswire Inc.
Read moreTargeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications
04/21 04:27 am
GlobeNewswire Inc.
Read moreOncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
04/21 04:14 am
GlobeNewswire Inc.
Read moreAlpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036
04/13 04:47 am
GlobeNewswire Inc.
Read moreWhich Dividend Pharma Stock Should a Value Investor Choose Today?
04/12 08:28 pm
The Motley Fool
Read more2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap
04/10 06:30 am
The Motley Fool
Read more7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments
04/10 04:59 am
GlobeNewswire Inc.
Read moreOxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
04/09 07:00 am
GlobeNewswire Inc.
Read moreInterstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight
04/08 01:00 pm
GlobeNewswire Inc.
Read moreTrump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime
04/06 01:20 pm
Investing.com
Read moreBile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed
03/30 06:00 am
GlobeNewswire Inc.
Read moreEsophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate
03/30 05:00 am
GlobeNewswire Inc.
Read moreWhat Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.
03/24 07:06 am
The Motley Fool
Read moreShould You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?
03/23 04:30 pm
The Motley Fool
Read moreBristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma
03/20 01:57 pm
Benzinga
Read moreCytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
03/17 10:46 pm
GlobeNewswire Inc.
Read moreThe $3B Biotech With Two Shots On Goal
03/17 07:07 am
Benzinga
Read more1 ETF That Could Turn $100 Per Month Into $67,380
03/15 05:05 am
The Motley Fool
Read moreWant Decades of Passive Income? Buy This Index Fund and Hold It Forever
03/14 05:14 am
The Motley Fool
Read moreBioNTech Stock Tumbles As Co-Founders Pivot To New MRNA Venture
03/10 08:40 am
Benzinga
Read moreAbecma (Bristol-Myers Squibb) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
03/10 05:46 am
GlobeNewswire Inc.
Read moreEditas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
03/09 07:00 am
GlobeNewswire Inc.
Read more2 Top Healthcare Dividend Stocks to Buy and Hold Forever
03/05 04:30 pm
The Motley Fool
Read moreCytokines Market Global Forecast 2026-2032: Precise Treatments, Strategic Partnerships, and Supply Chain Resilience Fueling the $95+ Billion Market
03/05 05:44 am
GlobeNewswire Inc.
Read moreOXB announces date for Capital Markets Day and participation in upcoming investor conferences
03/03 08:00 am
GlobeNewswire Inc.
Read more